Commitments and contingencies - Pfizer Option and License Agreement - (Details) $ in Thousands		12 Months Ended
	Oct. 01, 2021 USD ($) item	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized		$ 269
Collaboration revenue		40,907	$ 37,415	$ 171,128
Pfizer | Option and license agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of transgenes | item	2
Number of options | item	1
Number of performance obligations | item	2
Number of material rights | item	2
Upfront payment	$ 30,000
Non-refundable upfront payment received	$ 30,000
Number of license options | item	1
Allocation of transaction price	$ 15,000
Aggregate milestone payments, if exercise rights	$ 10,000	10,000
Revenue recognized		40,000
Collaboration revenue		40,000
Pfizer | First Material Right
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Allocation of transaction price		25,000
Pfizer | Second Material Right
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Allocation of transaction price		$ 15,000
Number of days written notice required by reporting entity to terminate agreement	90 days
Pfizer | Development, regulatory and commercialization milestone | Option and license agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate maximum milestone payments to be received from collaborative partner	$ 115,000
Pfizer | Sales milestone | Option and license agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate maximum milestone payments to be received from collaborative partner	$ 175,000
Minimum | Pfizer | Option and license agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of countries received regulatory approval | item	1
Number of major market countries received regulatory approval | item	1